Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes
- PMID: 28112737
- PMCID: PMC5687824
- DOI: 10.1038/ng.3772
Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes
Abstract
Acute megakaryoblastic leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) in which cells morphologically resemble abnormal megakaryoblasts. While rare in adults, AMKL accounts for 4-15% of newly diagnosed childhood AML cases. AMKL in individuals without Down syndrome (non-DS-AMKL) is frequently associated with poor clinical outcomes. Previous efforts have identified chimeric oncogenes in a substantial number of non-DS-AMKL cases, including RBM15-MKL1, CBFA2T3-GLIS2, KMT2A gene rearrangements, and NUP98-KDM5A. However, the etiology of 30-40% of cases remains unknown. To better understand the genomic landscape of non-DS-AMKL, we performed RNA and exome sequencing on specimens from 99 patients (75 pediatric and 24 adult). We demonstrate that pediatric non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups with varying outcomes. These subgroups are characterized by chimeric oncogenes with cooperating mutations in epigenetic and kinase signaling genes. Overall, these data shed light on the etiology of AMKL and provide useful information for the tailoring of treatment.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687824/bin/nihms916854f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687824/bin/nihms916854f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687824/bin/nihms916854f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5687824/bin/nihms916854f4.gif)
Similar articles
-
Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome.Genes Chromosomes Cancer. 2017 May;56(5):394-404. doi: 10.1002/gcc.22444. Epub 2017 Feb 14. Genes Chromosomes Cancer. 2017. PMID: 28063190
-
Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.Cold Spring Harb Mol Case Stud. 2021 Apr 8;7(2):a005975. doi: 10.1101/mcs.a005975. Print 2021 Apr. Cold Spring Harb Mol Case Stud. 2021. PMID: 33832921 Free PMC article.
-
[Prognostic significance of chimeric fusion gene analysis in pediatric acute megakaryoblastic leukemia].Rinsho Ketsueki. 2019;60(2):99-105. doi: 10.11406/rinketsu.60.99. Rinsho Ketsueki. 2019. PMID: 30842387 Japanese.
-
The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children.Crit Rev Oncol Hematol. 2019 Jun;138:132-138. doi: 10.1016/j.critrevonc.2019.04.011. Epub 2019 Apr 15. Crit Rev Oncol Hematol. 2019. PMID: 31092368 Review.
-
The biology of pediatric acute megakaryoblastic leukemia.Blood. 2015 Aug 20;126(8):943-9. doi: 10.1182/blood-2015-05-567859. Epub 2015 Jul 17. Blood. 2015. PMID: 26186939 Free PMC article. Review.
Cited by
-
Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults.Cancers (Basel). 2024 Feb 29;16(5):997. doi: 10.3390/cancers16050997. Cancers (Basel). 2024. PMID: 38473358 Free PMC article. Review.
-
Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.Ann Hematol. 2024 Apr;103(4):1103-1119. doi: 10.1007/s00277-024-05680-5. Epub 2024 Mar 6. Ann Hematol. 2024. PMID: 38443661 Free PMC article. Review.
-
Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene.J Pediatr Hematol Oncol. 2024 Mar 1;46(2):96-103. doi: 10.1097/MPH.0000000000002822. Epub 2024 Feb 1. J Pediatr Hematol Oncol. 2024. PMID: 38315896 Free PMC article.
-
A new genomic framework to categorize pediatric acute myeloid leukemia.Nat Genet. 2024 Feb;56(2):281-293. doi: 10.1038/s41588-023-01640-3. Epub 2024 Jan 11. Nat Genet. 2024. PMID: 38212634 Free PMC article.
-
CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.Blood Adv. 2024 Jan 9;8(1):112-129. doi: 10.1182/bloodadvances.2022008899. Blood Adv. 2024. PMID: 37729615 Free PMC article.
References
-
- Pagano L, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia. 2002;16:1622–6. - PubMed
-
- Athale UH, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood. 2001;97:3727–32. - PubMed
-
- Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2007;49:17–22. - PubMed
-
- Ma Z, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001;28:220–1. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical